I HOPE I CAUGHT YOU BEFORE IT'S TOO LATE

You Built the Device. Now What?

Let me paint you a picture.

A brilliant founder spends three, four, sometimes seven years developing a medical device. They run studies. They survive the FDA process. They get the 510(k). They pop the champagne.

Then they walk into a hospital and get absolutely nowhere.

Not because the device doesn’t work. It works great.

Not because there’s no clinical need. The need is obvious.

But because FDA clearance and hospital adoption are two entirely different games, governed by different rules, played by different people...and most founders only trained for one of them.

If you’re coming from outside the U.S., it’s even worse.

This is the gap Metamorph MedTech exists to close.

Why I Care About This Problem

I’m Rob. I’ve spent my career at the intersection of medtech, health economics, and commercial strategy long enough to know how this story usually ends when nobody intervenes early.

I’ve sat with founders who had peer-reviewed data and no reimbursement pathway.

I’ve watched companies clear FDA and spend eighteen months figuring out who actually makes the buying decision (spoiler: not the surgeon).

I’ve seen clinical studies designed around what the PI wanted with zero consideration for what the Value Analysis Committee needed to approve it.

And I’ve spent enough time inside healthcare systems to understand why.

Hospitals aren’t irrational. They’re optimizing for a completely different set of variables: risk, budget cycles, workflow disruption, and the opinions of a committee that may never meet your clinical champion.

Let’s just say it plainly - the system is built to say no. And somehow, it’s still the largest healthcare market in the world.

Time after time, I see companies running into the same problem:

Brilliant clinical innovation dying somewhere between the FDA letter and a signed purchase order.

What Actually Goes Wrong

Here’s what doesn’t make it into the pitch deck:

• The clinical champion problem: The surgeon who loves your device cannot buy your device. They can advocate for it, but the decision runs through procurement, finance, and a Value Analysis Committee with competing priorities. If your strategy is “our KOL will open doors,” you’re in for an expensive lesson.

• The study design problem: Most studies are designed to satisfy the FDA and the PI. That’s necessary, but not sufficient. The CFO wants cost per case. The payer wants outcomes tied to reimbursement. The CMO wants workflow impact. If your study doesn’t answer those questions, you’ll spend years fixing it after clearance.

• The economics problem: “This device will save the hospital money” is the most overused claim in medtech. Almost nobody can prove it cleanly without stacking assumptions. Hospitals have seen that deck. They’re not impressed.

• The reimbursement timing problem: Reimbursement isn’t a post-clearance problem. It’s not even a clinical trial problem. It’s a study design problem from day one. Ignore it early, and you pay for it later in delayed revenue and confused payers.

None of this is secret. It just shows up too late. And get this...this is only the start.

Because commercialization gets treated like a Phase 2 problem.

It’s not.

It’s a Phase 1 problem wearing a Phase 2 costume.

Why Metamorph?

I started Metamorph MedTech because I kept having these conversations anyway at conferences, over coffee, in quick calls that turned into “we should probably fix this.”

And I realized something:

The advice founders were getting in 30-minute conversations was often more actionable than what they were paying for in slide decks that never got implemented.

The thesis is simple:

Early-stage medtech and AI health companies need commercialization strategy built in from the beginning, not bolted on at the end.

That means:

• Clinical studies designed with the buyer in mind

• Economic models that hold up under scrutiny

• Reimbursement pathways scoped early

• Sales strategies aligned with how hospitals actually buy

Because hospitals don’t buy innovation.

They buy risk reduction with a budget code attached.

Who This Is For

1. If you’re a founder or executive at an early-stage medtech or AI health company navigating U.S. commercialization - payer strategy, hospital sales, VAC navigation, economic modeling - this is the work.

2. If you’re a consultant or operator in the space and want to collaborate or compare notes, even better.

3. And if you somehow found this while Googling “why is medtech commercialization so hard” late at night… welcome. You’re not wrong.

Metamorph MedTech is a consulting practice focused on go-to-market strategy, commercialization, and investor positioning for early-stage medtech and AI healthcare companies.